Literature DB >> 14640383

Protection from HIV-1 infection of primary CD4 T cells by CCR5 silencing is effective for the full spectrum of CCR5 expression.

Christophe Butticaz1, Angela Ciuffi, Miguel Muñoz, Jérôme Thomas, Alan Bridge, Stephanie Pebernard, Richard Iggo, Pascal Meylan, Amalio Telenti.   

Abstract

Stable gene silencing by RNA interference (RNAi) can be achieved by expression of small hairpin RNAs (shRNAs) from RNA polymerase III promoters. We have tested lentiviral vectors expressing shRNAs targetting CCR5 in primary CD4 T cells from donors representing various CCR5 and CCR2 genetic backgrounds covering the full spectrum of CCR5 expression levels and permissiveness for HIV-1 infection. A linear decrease in CCR5 expression resulted in a logarithmic decrease in cellular infection, giving up to three logs protection from HIV-1 infection in vitro. Protection was maintained at very high multiplicity of infection. This and other recent reports on RNAi should open a debate about the use of RNAi gene therapy for HIV infection.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14640383

Source DB:  PubMed          Journal:  Antivir Ther        ISSN: 1359-6535


  14 in total

Review 1.  Silence of the transcripts: RNA interference in medicine.

Authors:  Sailen Barik
Journal:  J Mol Med (Berl)       Date:  2005-07-19       Impact factor: 4.599

2.  Possible applications for replicating HIV 1 vectors.

Authors:  Atze T Das; Rienk E Jeeninga; Ben Berkhout
Journal:  HIV Ther       Date:  2010-05-01

3.  Antiviral effects of human immunodeficiency virus type 1-specific small interfering RNAs against targets conserved in select neurotropic viral strains.

Authors:  Rajnish S Dave; Roger J Pomerantz
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

Review 4.  Stem cell-based anti-HIV gene therapy.

Authors:  Scott G Kitchen; Saki Shimizu; Dong Sung An
Journal:  Virology       Date:  2011-01-17       Impact factor: 3.616

Review 5.  Lentiviral delivery of short hairpin RNAs.

Authors:  N Manjunath; Haoquan Wu; Sandesh Subramanya; Premlata Shankar
Journal:  Adv Drug Deliv Rev       Date:  2009-03-31       Impact factor: 15.470

6.  Entry and transcription as key determinants of differences in CD4 T-cell permissiveness to human immunodeficiency virus type 1 infection.

Authors:  Angela Ciuffi; Gabriela Bleiber; Miguel Muñoz; Raquel Martinez; Corinne Loeuillet; Manuela Rehr; Marek Fischer; Huldrych F Günthard; Annette Oxenius; Pascal Meylan; Sebastian Bonhoeffer; Didier Trono; Amalio Telenti
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

7.  Cell surface expression of CCR5 and other host factors influence the inhibition of HIV-1 infection of human lymphocytes by CCR5 ligands.

Authors:  Thomas J Ketas; Shawn E Kuhmann; Ashley Palmer; Juan Zurita; Weijing He; Sunil K Ahuja; Per Johan Klasse; John P Moore
Journal:  Virology       Date:  2007-04-10       Impact factor: 3.616

8.  DBR1 siRNA inhibition of HIV-1 replication.

Authors:  Ying Ye; Jessica De Leon; Noriko Yokoyama; Yathi Naidu; David Camerini
Journal:  Retrovirology       Date:  2005-10-18       Impact factor: 4.602

9.  Transfer and Expression of Small Interfering RNAs in Mammalian Cells Using Lentiviral Vectors.

Authors:  T D Lebedev; P V Spirin; V S Prassolov
Journal:  Acta Naturae       Date:  2013-04       Impact factor: 1.845

10.  CXCR4 and CCR5 shRNA transgenic CD34+ cell derived macrophages are functionally normal and resist HIV-1 infection.

Authors:  Joseph Anderson; Ramesh Akkina
Journal:  Retrovirology       Date:  2005-08-18       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.